Ron Blankstein1, Michael Osborne2, Masanao Naya3, Alfonso Waller3, Chun K Kim4, Venkatesh L Murthy5, Pedram Kazemian6, Raymond Y Kwong5, Michifumi Tokuda6, Hicham Skali5, Robert Padera7, Jon Hainer3, William G Stevenson6, Sharmila Dorbala3, Marcelo F Di Carli8. 1. Noninvasive Cardiovascular Imaging Program, Department of Medicine (Cardiovascular Division) and Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts; Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts. Electronic address: rblankstein@partners.org. 2. Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts. 3. Noninvasive Cardiovascular Imaging Program, Department of Medicine (Cardiovascular Division) and Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts. 4. Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts. 5. Noninvasive Cardiovascular Imaging Program, Department of Medicine (Cardiovascular Division) and Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts; Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts. 6. Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts. 7. Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts. 8. Noninvasive Cardiovascular Imaging Program, Department of Medicine (Cardiovascular Division) and Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts; Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts; Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Boston, Massachusetts.
Abstract
OBJECTIVES: This study sought to relate imaging findings on positron emission tomography (PET) to adverse cardiac events in patients referred for evaluation of known or suspected cardiac sarcoidosis. BACKGROUND: Although cardiac PET is commonly used to evaluate patients with suspected cardiac sarcoidosis, the relationship between PET findings and clinical outcomes has not been reported. METHODS: We studied 118 consecutive patients with no history of coronary artery disease, who were referred for PET, using [(18)F]fluorodeoxyglucose (FDG) to assess for inflammation and rubidium-82 to evaluate for perfusion defects (PD), following a high-fat/low-carbohydrate diet to suppress normal myocardial glucose uptake. Blind readings of PET data categorized cardiac findings as normal, positive PD or FDG, positive PD and FDG. Images were also used to identify whether findings of extra-cardiac sarcoidosis were present. Adverse events (AE)-death or sustained ventricular tachycardia (VT)-were ascertained by electronic medical records, defibrillator interrogation, patient questionnaires, and telephone interviews. RESULTS: Among the 118 patients (age 52 ± 11 years; 57% males; mean ejection fraction: 47 ± 16%), 47 (40%) had normal and 71 (60%) had abnormal cardiac PET findings. Over a median follow-up of 1.5 years, there were 31 (26%) adverse events (27 VT and 8 deaths). Cardiac PET findings were predictive of AE, and the presence of both a PD and abnormal FDG (29% of patients) was associated with hazard ratio of 3.9 (p < 0.01) and remained significant after adjusting for left ventricular ejection fraction (LVEF) and clinical criteria. Extra-cardiac FDG uptake (26% of patients) was not associated with AE. CONCLUSIONS: The presence of focal PD and FDG uptake on cardiac PET identifies patients at higher risk of death or VT. These findings offer prognostic value beyond Japanese Ministry of Health and Welfare clinical criteria, the presence of extra-cardiac sarcoidosis and LVEF.
OBJECTIVES: This study sought to relate imaging findings on positron emission tomography (PET) to adverse cardiac events in patients referred for evaluation of known or suspected cardiac sarcoidosis. BACKGROUND: Although cardiac PET is commonly used to evaluate patients with suspected cardiac sarcoidosis, the relationship between PET findings and clinical outcomes has not been reported. METHODS: We studied 118 consecutive patients with no history of coronary artery disease, who were referred for PET, using [(18)F]fluorodeoxyglucose (FDG) to assess for inflammation and rubidium-82 to evaluate for perfusion defects (PD), following a high-fat/low-carbohydrate diet to suppress normal myocardial glucose uptake. Blind readings of PET data categorized cardiac findings as normal, positive PD or FDG, positive PD and FDG. Images were also used to identify whether findings of extra-cardiac sarcoidosis were present. Adverse events (AE)-death or sustained ventricular tachycardia (VT)-were ascertained by electronic medical records, defibrillator interrogation, patient questionnaires, and telephone interviews. RESULTS: Among the 118 patients (age 52 ± 11 years; 57% males; mean ejection fraction: 47 ± 16%), 47 (40%) had normal and 71 (60%) had abnormal cardiac PET findings. Over a median follow-up of 1.5 years, there were 31 (26%) adverse events (27 VT and 8 deaths). Cardiac PET findings were predictive of AE, and the presence of both a PD and abnormal FDG (29% of patients) was associated with hazard ratio of 3.9 (p < 0.01) and remained significant after adjusting for left ventricular ejection fraction (LVEF) and clinical criteria. Extra-cardiac FDG uptake (26% of patients) was not associated with AE. CONCLUSIONS: The presence of focal PD and FDG uptake on cardiac PET identifies patients at higher risk of death or VT. These findings offer prognostic value beyond Japanese Ministry of Health and Welfare clinical criteria, the presence of extra-cardiac sarcoidosis and LVEF.
Authors: Joseph L Schuller; Matthew Zipse; Thomas Crawford; Frank Bogun; John Beshai; Amit R Patel; Nadera J Sweiss; Duy T Nguyen; Ryan G Aleong; Paul D Varosy; Howard D Weinberger; William H Sauer Journal: J Cardiovasc Electrophysiol Date: 2012-07-19
Authors: Peter Ott; Frank I Marcus; Richard E Sobonya; Fred Morady; Bradley P Knight; Charles E Fuenzalida Journal: Pacing Clin Electrophysiol Date: 2003-07 Impact factor: 1.976
Authors: Brian P Betensky; Cory M Tschabrunn; Erica S Zado; Lee R Goldberg; Francis E Marchlinski; Fermin C Garcia; Joshua M Cooper Journal: Heart Rhythm Date: 2012-02-13 Impact factor: 6.343
Authors: Kenneth A Ellenbogen; Joseph H Levine; Ronald D Berger; James P Daubert; Stephen L Winters; Eugene Greenstein; Alaa Shalaby; Andi Schaechter; Haris Subacius; Alan Kadish Journal: Circulation Date: 2006-02-06 Impact factor: 29.690
Authors: Sanjay Divakaran; Avinainder Singh; Bradley Collins; Tomas Vita; Rodney H Falk; Marcelo F Di Carli; Ron Blankstein Journal: Curr Treat Options Cardiovasc Med Date: 2017-01
Authors: Michael T Osborne; Edward A Hulten; Venkatesh L Murthy; Hicham Skali; Viviany R Taqueti; Sharmila Dorbala; Marcelo F DiCarli; Ron Blankstein Journal: J Nucl Cardiol Date: 2016-06-08 Impact factor: 5.952
Authors: Sanjay Divakaran; Garrick C Stewart; Neal K Lakdawala; Robert F Padera; Wunan Zhou; Akshay S Desai; Michael M Givertz; Mandeep R Mehra; Raymond Y Kwong; Sandeep S Hedgire; Brian B Ghoshhajra; Viviany R Taqueti; Hicham Skali; Sharmila Dorbala; Ron Blankstein; Marcelo F Di Carli Journal: Circ Cardiovasc Imaging Date: 2019-06-10 Impact factor: 7.792